Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Panita Decha, Pathumwadee Intharathep, Thanyarat Udommaneethanakit, Pornthep Sompornpisut, Supot Hannongbua, Peter Wolschann & Vudhichai Parasuk. (2011) Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions. Journal of Enzyme Inhibition and Medicinal Chemistry 26:1, pages 29-36.
Read now
Read now
Brookie M Best & Miguel Goicoechea. (2008) Efavirenz – Still First-line King?. Expert Opinion on Drug Metabolism & Toxicology 4:7, pages 965-972.
Read now
Read now
Articles from other publishers (16)
Zhao Wang, Prem Prakash Sharma, Brijesh Rathi, Minghui Xie, Erik De Clercq, Christophe Pannecouque, Dongwei Kang, Peng Zhan & Xinyong Liu. (2023)
Escaping from Flatland: Multiparameter Optimization Leads to the Discovery of Novel Tetrahydropyrido[4,3-
d
]pyrimidine Derivatives as Human Immunodeficiency Virus-1 Non-nucleoside Reverse Transcriptase Inhibitors with Superior Antiviral Activities against Non-nucleoside Reverse Transcriptase Inhibitor-Resistant Variants and Favorable Drug-like Profiles
. Journal of Medicinal Chemistry 66:13, pages 8643-8665.
Crossref
Crossref
Linlin Hu, Ting Dou, Qiuyue Sun, Lu Tang, Mingmin Cai, Wei Qian & Huiping Wang. (2023) Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects. Investigational New Drugs 41:2, pages 276-283.
Crossref
Crossref
Gerd Mikus, Tilman Heinrich, Julia Bödigheimer, Claudia Röder, Anne-Kathrin Matthee, Johanna Weiss, Jürgen Burhenne & Walter E. Haefeli. (2017) Semisimultaneous Midazolam Administration to Evaluate the Time Course of CYP3A Activation by a Single Oral Dose of Efavirenz. The Journal of Clinical Pharmacology 57:7, pages 899-905.
Crossref
Crossref
Mônica M. Bastos, Carolina C.P. Costa, Talitha C. Bezerra, Fernando de C. da Silva & Núbia Boechat. (2016) Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry. European Journal of Medicinal Chemistry 108, pages 455-465.
Crossref
Crossref
B. Armstrong, D. J. Chan, M. J. Stewart, D. Fagan & D. Smith. (2015) Single Tablet Regimen Usage and Efficacy in the Treatment of HIV Infection in Australia. AIDS Research and Treatment 2015, pages 1-5.
Crossref
Crossref
Eric N. Ouattara, Xavier Anglaret, Angela Y. Wong, Jennifer Chu, Heather E. Hsu, Christine Danel, Serge Eholié, Raoul Moh, Delphine Gabillard, Rochelle P. Walensky & Kenneth A. Freedberg. (2012) Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age. AIDS 26:5, pages 625-634.
Crossref
Crossref
N L Katende-Kyenda, M S Lubbe, J H P Serfontein & I Truter. (2012) Identification of potential drug–drug interactions between antiretroviral drugs from prescriptions in the private health-care sector in South Africa. International Journal of STD & AIDS 23:3, pages 166-172.
Crossref
Crossref
Manfred Marschall, Thomas Stamminger, Andreas Urban, Steffen Wildum, Helga Ruebsamen-Schaeff, Holger Zimmermann & Peter Lischka. (2012)
In Vitro
Evaluation of the Activities of the Novel Anticytomegalovirus Compound AIC246 (Letermovir) against Herpesviruses and Other Human Pathogenic Viruses
. Antimicrobial Agents and Chemotherapy 56:2, pages 1135-1137.
Crossref
Crossref
Romuald Corbau, Julie Mori, Chris Phillips, Lesley Fishburn, Alex Martin, Charles Mowbray, Wendy Panton, Caroline Smith-Burchnell, Adele Thornberry, Heather Ringrose, Thorsten Knöchel, Steve Irving, Mike Westby, Anthony Wood & Manos Perros. (2010) Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1. Antimicrobial Agents and Chemotherapy 54:10, pages 4451-4463.
Crossref
Crossref
Natasza E. Ziółkowska, Christopher J. Michejda & Grzegorz D. Bujacz. (2010) Structural studies of series HIV-1 nonnucleoside reverse transcriptase inhibitors 1-(2,6-difluorobenzyl)-2-(2,6-difluorophenyl)-benzimidazoles with different 4-substituents. Journal of Molecular Structure 966:1-3, pages 53-58.
Crossref
Crossref
Natasza E. Ziółkowska, Christopher J. Michejda & Grzegorz D. Bujacz. (2010) Structure of HIV-1 nonnucleoside reverse transcriptase inhibitors derivatives of N-benzyl-benzimidazole with different substituents in position 4. Journal of Molecular Structure 963:2-3, pages 188-193.
Crossref
Crossref
Oliver Koch, Susanne Sheehy, Catherine Sargent, Jane Democratis, Sarah Abbas, Jurgen Schiefermueller & Brian J. Angus. 2010. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions
529
553
.
Natasza E. Ziółkowska, Christopher J. Michejda & Grzegorz D. Bujacz. (2009) Structural investigation of HIV-1 nonnucleoside reverse transcriptase inhibitors: 2-Aryl-substituted benzimidazoles. Journal of Molecular Structure 937:1-3, pages 34-38.
Crossref
Crossref
Johanna Weiss, Melanie Herzog, Sonja König, Caroline Henrike Storch, Nahal Ketabi-Kiyanvash & Walter Emil Haefeli. (2009) Induction of Multiple Drug Transporters by Efavirenz. Journal of Pharmacological Sciences 109:2, pages 242-250.
Crossref
Crossref
Emilio L. Streck, Giselli Scaini, Gislaine T. Rezin, Jeverson Moreira, Celine M. Fochesato & Pedro R. T. Romão. (2008) Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity. Metabolic Brain Disease 23:4, pages 485-492.
Crossref
Crossref
Dirk Jochmans. (2008) Novel HIV-1 reverse transcriptase inhibitors. Virus Research 134:1-2, pages 171-185.
Crossref
Crossref